Assenagon Asset Management S.A. Sells 283,399 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

Assenagon Asset Management S.A. trimmed its stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 33.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 573,173 shares of the biotechnology company's stock after selling 283,399 shares during the period. Assenagon Asset Management S.A. owned 1.14% of REGENXBIO worth $4,098,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its position in shares of REGENXBIO by 67.0% in the fourth quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock worth $31,975,000 after purchasing an additional 1,659,206 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in REGENXBIO by 9.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company's stock valued at $185,000 after acquiring an additional 1,982 shares during the period. BNP Paribas Financial Markets lifted its position in shares of REGENXBIO by 370.1% in the fourth quarter. BNP Paribas Financial Markets now owns 96,093 shares of the biotechnology company's stock valued at $743,000 after acquiring an additional 75,652 shares in the last quarter. Wells Fargo & Company MN grew its position in shares of REGENXBIO by 34.0% during the fourth quarter. Wells Fargo & Company MN now owns 48,437 shares of the biotechnology company's stock worth $374,000 after purchasing an additional 12,285 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in REGENXBIO in the 4th quarter worth approximately $568,000. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

REGENXBIO Price Performance

Shares of NASDAQ:RGNX traded down $0.09 during trading on Thursday, hitting $8.57. The company had a trading volume of 998,085 shares, compared to its average volume of 927,787. The stock has a market cap of $429.87 million, a price-to-earnings ratio of -2.76 and a beta of 1.09. The company has a fifty day simple moving average of $8.64 and a two-hundred day simple moving average of $7.93. REGENXBIO Inc. has a one year low of $5.04 and a one year high of $15.36.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.41 by ($0.29). The company had revenue of $89.01 million during the quarter, compared to the consensus estimate of $105.35 million. REGENXBIO had a negative return on equity of 53.29% and a negative net margin of 100.62%. On average, equities research analysts anticipate that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Insider Activity

In other REGENXBIO news, Director Kenneth T. Mills sold 20,602 shares of the firm's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $7.91, for a total value of $162,961.82. Following the completion of the sale, the director now owns 475,103 shares of the company's stock, valued at $3,758,064.73. This trade represents a 4.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 12.79% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Chardan Capital reaffirmed a "buy" rating and set a $52.00 target price on shares of REGENXBIO in a research note on Monday, June 9th. HC Wainwright reduced their target price on REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a report on Monday, March 17th. Morgan Stanley increased their price target on REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a research note on Friday, March 14th. Leerink Partners set a $24.00 price objective on REGENXBIO in a research note on Tuesday, March 18th. Finally, Wall Street Zen upgraded REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $31.63.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.